Answers are grounded in this paper and cite their sources.
T cells. FAP- and CD19-4-1BBL thus represent an off-the-shelf combination immunotherapy without requiring genetic modification of effector cells for the treatment of solid and hematological malignancies.
No takes yet. Share an insight, caveat, or question.
Claus et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: